The Johns Hopkins University (20240376143). SELECTION INHIBITION OF DNA POLYMERASE BETA BY A COVALENT INHIBITOR simplified abstract
Contents
- 1 SELECTION INHIBITION OF DNA POLYMERASE BETA BY A COVALENT INHIBITOR
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 SELECTION INHIBITION OF DNA POLYMERASE BETA BY A COVALENT INHIBITOR - A simplified explanation of the abstract
- 1.4 Potential Applications
- 1.5 Problems Solved
- 1.6 Benefits
- 1.7 Commercial Applications
- 1.8 Questions about the Technology
- 1.9 Original Abstract Submitted
SELECTION INHIBITION OF DNA POLYMERASE BETA BY A COVALENT INHIBITOR
Organization Name
Inventor(s)
Marc M. Greenberg of Baltimore MD (US)
Shelby C. Yuhas of Baltimore MD (US)
SELECTION INHIBITION OF DNA POLYMERASE BETA BY A COVALENT INHIBITOR - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240376143 titled 'SELECTION INHIBITION OF DNA POLYMERASE BETA BY A COVALENT INHIBITOR
The patent application discloses methods and compounds for irreversibly inhibiting a DNA polymerase, specifically DNA polymerase β (pol β). Additionally, the application describes methods for inducing synthetic lethality in BRCA1-deficient cancer cells by inhibiting DNA polymerase β with a newly developed inhibitor.
- The patent application introduces a novel method for targeting DNA polymerase β to inhibit its function irreversibly.
- The innovation includes a synthetic lethality approach to selectively kill BRCA1-deficient cancer cells by exploiting their specific vulnerability.
- The disclosed pol β inhibitor has the potential to be a targeted therapy for a subset of breast cancer patients with BRCA1 mutations.
- This technology offers a promising strategy for enhancing the efficacy of cancer treatment by exploiting genetic vulnerabilities in cancer cells.
- The patent application provides a new avenue for personalized medicine in the treatment of breast cancer, particularly in patients with BRCA1 mutations.
Potential Applications
The technology has potential applications in cancer therapy, specifically in the treatment of BRCA1-deficient breast cancer. It could also be explored for other types of cancer with similar genetic vulnerabilities.
Problems Solved
This technology addresses the challenge of selectively targeting cancer cells with specific genetic mutations, such as BRCA1 deficiency, while minimizing harm to normal cells. It offers a precision medicine approach to cancer treatment.
Benefits
The technology offers a targeted and personalized approach to cancer therapy, potentially improving treatment outcomes for patients with BRCA1 mutations. It may lead to more effective and less toxic treatment options for a subset of breast cancer patients.
Commercial Applications
- The technology could be developed into a targeted therapy for BRCA1-deficient breast cancer, potentially entering the market as a precision medicine treatment.
- Pharmaceutical companies could explore the development of pol β inhibitors for cancer therapy, targeting specific genetic vulnerabilities in cancer cells.
Questions about the Technology
How does the pol β inhibitor specifically target BRCA1-deficient cancer cells?
The pol β inhibitor exploits the synthetic lethality concept, where inhibiting pol β in BRCA1-deficient cells leads to cell death due to their inability to repair DNA damage effectively.
What are the potential challenges in translating this technology into clinical applications?
One potential challenge could be ensuring the specificity and efficacy of the pol β inhibitor in clinical settings, as well as addressing potential resistance mechanisms that cancer cells may develop.
Original Abstract Submitted
methods and compounds are disclosed for irreversibly inhibiting a dna polymerase, including dna polymerase � (pol �). also disclosed are methods for inducing a synthetic lethality in a breast cancer type 1 (brca1)-deficient cancer cell, the method comprising inhibiting dna polymerase � by administering a presently disclosed pol � inhibitor.
